ARMP 10-Q filed 2026-11-12 | Key takeaways
ARMP filed its 10-Q; the most relevant disclosure change is expanded MTEC Award: The MTEC Agreement was modified on September 18, 2026 to increase the total award by $3.7 million to $32.4 million and extend the term to December 31, 2026; the award supports the AP-SA02 Phase 3 preparation activities.
Key takeaways
MTEC Award expanded to $32.4M: The MTEC Award was increased by $3.7M on September 18, 2026 to $32.4M and extended to December 31, 2026; the award supports the AP-SA02 bacteremia Phase 3 preparation and activities.
New $25.0M term loan executed: On May 12, 2026, the company entered into a secured term loan with Innoviva Strategic Opportunities LLC at 14.0% interest, maturing January 11, 2029.
Debt and warrant amendments completed: On January 23, 2026, maturity dates for the 2023, 2024, March 2025, and Convertible Credit Agreements were extended to June 1, 2027, and certain warrants were extended to January 26, 2031.
AP-SA02 regulatory milestones: The FDA granted Breakthrough Therapy Designation on September 14, 2026, in addition to existing QIDP and Fast Track designations; Phase 3 protocol was submitted to FDA.
Phase 3 manufacturing progress: The company completed four engineering runs and one cGMP production run of AP-SA02 at its in-house cGMP manufacturing facility during Q3 2026.
Going concern disclosure: Existing cash of $18.3M will not be sufficient to fund operations for the next 12 months from the filing date; the company plans to raise additional capital.
Stock-based compensation surge: Stock-based compensation expense increased to $2.2M in Q3 2026 versus $0.6M in Q3 2025, and to $6.7M for the nine months ended September 30, 2026 versus $2.0M in the prior year period.
Key metrics
Disclosure changes
- MTEC Award
The MTEC Agreement was modified on September 18, 2026 to increase the total award by $3.7 million to $32.4 million and extend the term to December 31, 2026; the award supports the AP-SA02 Phase 3 preparation activities.
The MTEC Award is non-dilutive funding supporting the company's Phase 3 clinical study preparation for AP-SA02; the expansion to $32.4M provides additional runway for clinical activities. - Convertible Loan fair value methodology
During the nine months ended September 30, 2026, the company estimated the fair value of the Convertible Loan on an as-converted basis, assuming a 100% conversion into equity; the Convertible Loan balance decreased to $94.309M from $153.860M at December 31, 2025.
The change in valuation methodology drove a $69.6M gain in Q3 2026 versus a $14.6M loss in Q3 2025, significantly impacting net income; this is a non-cash item. - 2026 Debt and Warrant Amendments
On January 23, 2026, the company entered into amendments extending maturity dates of the 2023, 2024, March 2025, and Convertible Credit Agreements to June 1, 2027; warrants were extended to January 26, 2031; this was accounted for as a troubled debt restructuring.
The extension provides additional time before debt maturities but increases interest expense and establishes a revised effective interest rate of 36.19% for the amended term loans. - AP-SA02 regulatory designations
The FDA granted Breakthrough Therapy Designation to AP-SA02 on September 14, 2026, in addition to existing QIDP (February 2026) and Fast Track (May 2026) designations; these designations provide for expedited development review, eligibility for accelerated approval and priority review, and an additional five-year extension of Hatch-Waxman market exclusivity.
Breakthrough Therapy Designation is the most significant regulatory milestone, providing comprehensive FDA support for efficient clinical development and review. - Phase 3 clinical study preparation
The company submitted the complete Phase 3 superiority protocol to the FDA, submitted responses to FDA comments, completed four engineering runs and one cGMP production run of AP-SA02, advanced qualification of QC release assays, and executed contracts with CROs; the Phase 3 study is expected to enroll approximately 550 patients with a primary endpoint at Day 70.
Phase 3 initiation is contingent on FDA concurrence with the protocol; the study design supports a potential BLA filing for AP-SA02. - Stock-based compensation expense
Stock-based compensation expense increased to $2.216M in Q3 2026 versus $0.622M in Q3 2025, and to $6.682M for the nine months ended September 30, 2026 versus $1.978M in the prior year period, primarily due to higher grant-date fair values of option grants made in 2026.
The increase in stock-based compensation expense reflects the company's equity compensation strategy and higher valuations; total unrecognized compensation expense was $12.9M as of September 30, 2026.
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow ARMP in real time
Get material earnings, filing, IR, and earnings-call alerts by email.